NJ-LABVANTAGE
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, has made available its semantic search (AILANI), advanced analytics, and LIMS solutions in an integrated, digitally native ecosystem capable of seamlessly supporting R&D laboratory processes. This ecosystem will enable R&D labs to improve efficiency, productivity, decision-making, collaboration, and ultimately time-to-market while reducing operational cost. LabVantage will present its LIMS solutions and integrated ecosystem at Pittcon 2024 (Booth #2133), February 24-28, in San Diego, California.
Digitizing R&D laboratory processes with advanced technologies such as semantic search, analytics, and LIMS marks a significant leap towards efficiency and innovation in the scientific domain. Semantic search capabilities enable the contextualization and searchability of vast amounts of data and documents, utilizing a semantic core and knowledge graph. This technology not only streamlines information retrieval and drastically reduces repetition in experimental runs, but also enhances the decision-making process by providing more relevant and precise data insights. Some LabVantage customers have experienced a 30% reduction in repeated experiments by implementing LabVantage’s semantic search tool, AILANI.
Integrating AI and Business Intelligence into a unified analytics platform, in tandem with LIMS, accelerates analysis and reporting. LabVantage Analytics provides analysis of both structured and unstructured data from diverse sources, integrating data processing, storage, analysis, and visualization in one platform. Its user-friendly self-service features include customizable dashboards and immediate access to LIMS data reports.
“By incorporating advanced technologies like semantic search, AI, and analytics into our LIMS solutions, we're not only enhancing data precision and reducing experimental repetition but also driving significant improvements in collaboration and experiment design. Together, these tools will be instrumental in enabling customers to design better experiments while drastically reducing the total number of experimental runs,” said Alan Marcus, Chief Growth Officer at LabVantage Solutions. “Our goal is to hand back more time to customers for scientific exploration. In fact, we believe these digitally native solutions will expand our ability to serve clients in all supported industries throughout their entire product lifecycle. Your data can now be unified, housed, searched, and analyzed within a single platform from concept to market.”
The implementation of a LIMS automates and manages laboratory workflows, significantly boosting efficiency and consistency in experiment execution. By integrating with search and analytics tools, LabVantage LIMS ensures a seamless flow of information, further elevating laboratory operations, decision-making, and collaboration. Industry statistics underscore the transformative impact of such digitization and automation with laboratories reporting up to a 30-40% increase in productivity.1
LabVantage’s merger with Biomax Informatics has enhanced its analytics and LIMS solutions by integrating AILANI, an advanced semantic search tool. AILANI synergizes semantic modeling, ontologies, linguistics, and AI algorithms to revolutionize query-based research. This tool effectively connects various data sources—internal, external, and proprietary—empowering researchers to swiftly discover valuable insights and hidden patterns. It also simplifies and accelerates decision-making throughout the R&D process by offering easy access to relevant information and its context.
LabVantage Biomax was recognized in the Gartner® Hype Cycle™ for Life Science Discovery Research 2023 as a Sample Vendor for two categories: ‘Semantic Knowledge Graph Tools’ and ‘Analytics Platforms for Research Informatics’.2 Similarly, LabVantage was ranked as a top growth and innovation leader in 2023 by Frost & Sullivan in the firm’s first annual global life sciences LIMS report and radar, highlighting LabVantage's commitment and status as a pivotal player in transforming life science research and analytics.
For more information on LabVantage, its LIMS solutions, and digitally native R&D ecosystem, visit www.labvantage.com or email info@labvantage.com.
References:
- McKinsey & Company. Digitization, Automation, and Online Testing: The Future of Pharma Quality Control. McKinsey & Company Life Sciences.
-
Harwood, R. Gartner® Hype Cycle™ for Life Science Discovery Research, 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222841525/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
The Earthshot Prize and 500 Global Announce Strategic Partnership to Advance Climate Innovation in Emerging Markets5.11.2025 01:01:00 CET | Press release
500 Global and The Earthshot Prize are partnering on an investment strategy to identify, support and scale climate solutions across Emerging Markets.Supporting three themes at the intersection of climate impact and commercial viability: AgTech, Clean Tech, and Nature Tech.The strategy was announced at The Earthshot Prize Summit in Rio De Janeiro ahead of the 2025 Earthshot Prize Awards Night, targeting to roll out H1 of 2026. 500 Global, one of the world’s most active venture capital firms and The Earthshot Prize, the world’s most prestigious and impactful environmental award, are announcing today a new strategic partnership to accelerate climate innovation in Emerging Markets, as climate finance is more relevant than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104586243/en/ 500 Global intends to develop and implement an investment strategy designed to de-risk early-stage investments, unlocking private cap
Cooler Master Announces the QUBE 540 PC Case, a Compact Size with Unlimited Creativity4.11.2025 23:58:00 CET | Press release
Designed for Creators, Gamers, and DIY Builders Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the QUBE 540, a compact case for today. The QUBE 540 offers orientation flexibility, so you can build a vertical or horizontal system that fits your desk or shelf. Inside, a modular interior lets you tailor the layout to your components and airflow preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104224092/en/ The QUBE 540 (Stardust Iron) with 3D-printed additions holding headphones and keyboard. The QUBE 540 keeps the clean, geometric design language of the QUBE series while raising the bar on practical adaptability. It fits comfortably in limited spaces such as small apartments and dorm rooms, and it looks at home in creator studios and living areas. The case ships in two colors, Moonstone or Stardust Iron, giving users options that blend with modern setups and room aes
IFF Reports Third Quarter 2025 Results4.11.2025 23:12:00 CET | Press release
Reaffirms Full Year 2025 Financial Guidance IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our innovation and commercial capabilities - and a sales reduction in Food Ingredients as we focus on driving higher margins.” “Profitability in the quarter improved high-single digits year-over-year, with margin expansion driven predominantly by productivity. By maintaining a disciplined focus on operational excellence, we are driving sustained profitability while investing in IFF for long-term success.” “In a more challenging environment, we’re doing what we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom